Table 2.
Final design of the PharmArray 180 SNPs format
| Gene | Rs# | No. of SNPs | Treatment |
|---|---|---|---|
| ABCB1 | rs2032582*; rs1045642*; rs3213619; rs1128503 | 4 | Immunosuppressants and antiplatelet drugs |
| ABCC2 | rs717620; rs56296335**; rs3740066; rs56199535*; rs56220353* | 5 | Tenofovir (antiretroviral agent) |
| ABCG2 | rs2231142; rs2273697; rs72552713 | 3 | Statins, Methotrexate (cytotoxic agent), Imatinib (tyrosine‐kinase inhibitor) |
| APOE | rs7412 | 1 | Anticoagulants, Pravastatin (Statin) |
| COMT | rs4680 | 1 | Nicotine |
| CFTR | rs75527207; rs113993960; rs199826652; rs267606723*; rs193922525; rs80282562; rs121909013; rs74503330; rs121909041; rs121908755*; rs121909005; rs121908757 | 12 | Ivacaftor (CFTR potentiator) |
| CYP2C19 | rs4244285*; rs4986893; rs12248560*; rs28399504; rs56337013; rs72552267; rs72558186; rs41291556 | 8 | Voriconazole (triazole antifungal agent), antiplatelet and psychotropic therapy |
| CYP2C8 | rs11572080; rs10509681; rs1058930; rs11572103 | 4 | Paclitaxel (cytotoxic agent), psychotropic therapy and oral antidiabetic agents |
| CYP2C9 | rs1799853; rs1057910 | 2 | Anticoagulants, psychotropic therapy |
| CYP2D6 | rs1080985; rs28371725; rs35742686; rs3892097; rs5030655; rs5030865*; rs5030867; rs5030656; rs1065852; rs1058164; rs1135840; rs16947; rs28371706; rs61736512; rs769258 | 15 | Psychotropic therapy, opioids |
| CYP3A4 | rs55785340; rs4646438 | 2 | Immunosuppressants |
| CYP3A5 | rs776746; rs55965422*; rs10264272; rs41303343; rs41279854 | 5 | Tacrolimus (immunosuppressant) |
| CYP4F2 | rs2108622 | 1 | Anticoagulants |
| DPYD | rs3918290; rs55886062*; rs55886062*; rs67376798; rs1801159; rs1801265 | 6 | Fluoropyrimidines (Cytotoxic agents) |
| ERCC1 | rs11615; rs3212986 | 2 | Cisplatin (cytotoxic agent) |
| EPHX1 | rs1051740 | 1 | Cisplatin (cytotoxic agent) |
| FCGR2A | rs1801274 | 1 | Biological therapy |
| HTR2A | rs6311 | 1 | Psychotropic therapy |
| IL10 | rs1800896; rs1800872; rs1800871 | 3 | Biological therapy |
| IL23R | rs7517847; rs10489629; rs11465804; rs1343151 | 4 | Biological therapy |
| KCNJ6 | rs2070995 | 1 | Analgesics |
| MTHFR | rs1801133; rs4846051; rs1801131 | 3 | Methotrexate (cytotoxic agent) |
| POR | rs1057868; rs2868177 | 2 | Immunosuppressants |
| SLC15A2 | rs2293616; rs2257212; rs1143671; rs1143672 | 4 | Others |
| SLC22A1 | rs72552763; rs55918055*; rs36103319*; rs34059508*; rs628031; rs4646277; rs2282143; rs4646278*; rs12208357 | 9 | Tramadol (Opioid), Metformin (oral antidiabetic agent) |
| SLC22A2 | rs316019; rs8177516; rs8177517; rs8177507*; rs8177504 | 5 | Fampridine (potassium channel‐blocking agent), Metformin (oral antidiabetic agent) |
| SLC22A6 | rs11568626 | 1 | Others |
| SLCO1B1 | rs4149056; rs2306283; rs56101265; rs72559745; rs56061388; rs55901008*; rs59502379; rs56199088*; rs55737008; rs4149015 | 10 | Statins, Irinotecan (cytotoxic agent), oral antidiabetic agents, conjugated estrogens |
| TLR2 | rs4696480; rs11938228 | 2 | Biological therapy |
| TLR9 | rs352139 | 1 | Biological therapy |
| TNF | rs1800629 | 1 | Biological therapy |
| TP53 | rs1042522 | 1 | Cisplatin (cytotoxic agent) |
| TPMT | rs1800460; rs1800462; rs1142345; rs1800584 | 4 | Thioguanines |
| UGT1A1 | rs887829; rs4148323; rs34993780; rs35350960; rs55750087; rs4124874 | 6 | Irinotecan (cytotoxic agent) |
| UGT2B7 | rs7438135 | 1 | Morphine, micophenolate (immunosuppressant) |
| VKORC1 | rs9934438 | 1 | Anticoagulants |
| XPC | rs2228001 | 1 | Cisplatin (cytotoxic agent) |
| XRCC1 | rs25487 | 1 | Cisplatin (cytotoxic agent) |
The table shows the final selection of SNPs (dbSNP b146) and genes included in our custom array. We also included two sex markers (rs768983 and rs3913290) for internal quality control of the genotyping process and the SNPs‐related drugs. SNPs followed by * are reported to have more than two allelic variants.